Plain-English translation of NCT06557460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called the CPCB-RPE1 implant, which is placed surgically under the retina in people with advanced dry macular degeneration (a condition that causes vision loss in the center of your eye). The implant is designed to replace damaged cells in the eye and may help slow or restore vision loss. About two-thirds of participants will receive the actual implant surgery, while the rest will receive a simulated procedure to help researchers fairly measure the true benefit.
Advanced dry macular degeneration, especially a condition called geographic atrophy, causes progressive vision loss and currently has no approved treatment to restore sight. This trial exists to see whether this new cell implant can help people maintain or improve their vision.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will undergo eye surgery under anesthesia to implant the new treatment or receive a simulated procedure. You will need to position yourself in a specific way after surgery (such as face-down) while your eye heals and use prescribed eye drops. You will attend follow-up visits at the study center so doctors can monitor your vision, eye health, and any side effects over time. About two-thirds of participants will receive the actual implant, while one-third will receive the sham procedure.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States